Accueil   Diary - News   All news Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH

Poxel Announces Initiation of Part 2 of Phase 1a Study for PXL065, which is being Developed for the Treatment of NASH

PXL065 data to date suggest the potential for a favorable profile for the treatment of NASH

 

 

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that Part 2 of the Phase 1a study for PXL065, a deuterium-stabilized R-stereoisomer of pioglitazone, has been initiated. This second part of the Phase 1a study will enroll six healthy subjects per group, with a primary objective to assess safety and tolerability and a secondary objective to assess dose proportionality. This Phase 1a trial, which was discussed with the U.S. Food and Drug Administration (FDA) in a pre-Investigational New Drug Application (IND) meeting, was designed to include two single oral doses and potentially up to three additional doses of PXL065.

 

 

Read the press release